Limits...
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.

Poon K, King AB - Drug Healthc Patient Saf (2010)

Bottom Line: Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action.Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles.Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir.

View Article: PubMed Central - PubMed

Affiliation: Diabetes Care Center, Salinas, CA, USA.

ABSTRACT
Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles. Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review summarizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical and observational studies to elucidate the role of each basal insulin analog in therapy.

No MeSH data available.


Related in: MedlinePlus

Molecular structures of insulin glargine and insulin detemir.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108694&req=5

f1-dhps-2-213: Molecular structures of insulin glargine and insulin detemir.

Mentions: Insulin glargine (GlyA21 ArgB21 ArgB32 human insulin) is synthesized via recombinant DNA technology using Escherichia coli K12.13 The amino acid asparagine at position A21 in human insulin is replaced with glycine, and two arginines are added to the C-terminus of the β-chain (Figure 1a).13 These modifications cause a shift in the isoelectric point towards neutrality. At a pH of 4 in acidic solution, glargine is not soluble at physiologic neutral pH and forms a microprecipitate upon injection into subcutaneous tissue.13


Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.

Poon K, King AB - Drug Healthc Patient Saf (2010)

Molecular structures of insulin glargine and insulin detemir.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108694&req=5

f1-dhps-2-213: Molecular structures of insulin glargine and insulin detemir.
Mentions: Insulin glargine (GlyA21 ArgB21 ArgB32 human insulin) is synthesized via recombinant DNA technology using Escherichia coli K12.13 The amino acid asparagine at position A21 in human insulin is replaced with glycine, and two arginines are added to the C-terminus of the β-chain (Figure 1a).13 These modifications cause a shift in the isoelectric point towards neutrality. At a pH of 4 in acidic solution, glargine is not soluble at physiologic neutral pH and forms a microprecipitate upon injection into subcutaneous tissue.13

Bottom Line: Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action.Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles.Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir.

View Article: PubMed Central - PubMed

Affiliation: Diabetes Care Center, Salinas, CA, USA.

ABSTRACT
Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles. Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review summarizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical and observational studies to elucidate the role of each basal insulin analog in therapy.

No MeSH data available.


Related in: MedlinePlus